Novartis' Radioligand Therapy Hits Primary Endpoint Goal In Prostate Cancer Study

Novartis AG NVS says that its Phase 3 VISION study of 177Lu-PSMA-617 hit both co-primary endpoints on overall survival and radiographic progression-free survival for prostate cancer patients. Details were not disclosed.

  • Investigators tried to treat progressive PSMA-positive metastatic castration-resistant prostate cancer patients, comparing it against the standard of care.
  • The VISION trial results will be presented at an upcoming medical meeting and included in U.S. and E.U. regulatory submissions.
  • 177Lu-PSMA-617 is an investigational PSMA-targeted radioligand therapy, a type of precision cancer treatment combining a targeting compound (ligand) with a therapeutic radioisotope.
  • After administration into the bloodstream, 177Lu-PSMA-617 binds to prostate cancer cells that express PSMA, a transmembrane protein, with high tumor-to-normal tissue uptake.
  • Once bound, emissions from the radioisotope damage tumor cells, disrupting their ability to replicate and triggering cell death.
  • Price Action: NVS shares are trading 0.49% lower at $86.09 in market trading hours on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareFDAGeneralprostate cancer
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!